Max Robotics — Global Service Robot Directory + US Certification

About

Kyohei Sugiyama is a urological surgeon and researcher whose work focuses on optimizing surgical outcomes in robot-assisted radical prostatectomy, particularly regarding perioperative bleeding and anticoagulation management. His most cited study, "Effects of thienopyridine class antiplatelets on bleeding outcomes following robot-assisted radical prostatectomy" (2024, 7 citations), provides critical evidence on the safety of continuing thienopyridine-class agents—including ticlopidine, clopidogrel, and prasugrel—during robotic prostate surgery. By leveraging a large cohort database, Sugiyama demonstrated that these antiplatelet drugs do not significantly increase bleeding complications, challenging previous clinical assumptions and offering clearer guidance for urologists managing patients on such therapies. This work has immediate implications for reducing unnecessary surgical delays and improving patient care in high-risk populations. Sugiyama’s research bridges the gap between cardiovascular pharmacology and urologic oncology, making him a key voice in evidence-based perioperative management. His contributions are particularly valuable for trainees and clinicians navigating the complex intersection of antithrombotic therapy and minimally invasive surgery.